I agree that this site is using cookies. You can find further informations here.
X
O'Hear, Carol E.
43  results:
Search for persons X
?
1

PI3K orchestration of the in vivo persistence of chimeric a..:

Zheng, Wenting ; O'Hear, Carol E. ; Alli, Rajshekhar...
Leukemia.  32 (2018)  5 - p. 1157-1167 , 2018
Link: https://doi.org/10.1038/..
 
?
2

Antibody Buffering of a Ligand in vivo:

O'Hear, Carol E. ; Foote, Jefferson ; Eisen, Herman N.
Proceedings of the National Academy of Sciences of the United States of America.  102 (2005)  1 - p. 40-44 , 2005
Link: https://www.jstor.org/st..
 
?
3

Antibody buffering of a ligandin vivo:

O'Hear, Carol E. ; Foote, Jefferson
Proceedings of the National Academy of Sciences.  102 (2004)  1 - p. 40-44 , 2004
Link: https://doi.org/10.1073/..
 
?
4

PI3K orchestration of the in vivo persistence of chimeric a..:

Zheng, Wenting ; O'Hear, Carol E ; Alli, Rajshekhar...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943191/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
5

Antibody buffering of a ligand in vivo:

O'Hear, Carol E ; Foote, Jefferson
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC544049.  , 2005
Link: http://www.ncbi.nlm.nih...
 
?
6

Gemtuzumab ozogamicin can reduce minimal residual disease i..:

O'Hear, Carol ; Inaba, Hiroto ; Pounds, Stanley...
Cancer.  119 (2013)  22 - p. 4036-4043 , 2013
Link: https://doi.org/10.1002/..
 
?
7

Single-Agent Mosunetuzumab Shows Durable Complete Responses..:

Budde, Lihua E ; Assouline, Sarit ; Sehn, Laurie H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824395/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease i..:

O'Hear, Carol ; Inaba, Hiroto ; Pounds, Stanley...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC.  , 2013
Link: http://www.ncbi.nlm.nih...
 
?
9

High-Dose Chemotherapy With Autologous Stem-Cell Rescue In ..:

Eckstein, O.S. ; O'Hear, C.E. ; Chi, S...
Biology of Blood and Marrow Transplantation.  16 (2010)  2 - p. S247 , 2010
Link: https://doi.org/10.1016/..
 
?
10

Poster: MDS-445 Magrolimab In Combination With Azacitidine ..:

Sallman, David ; Malki, Monzr Al ; Asch, Adam...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S151 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Poster: IBCL-249 Mosunetuzumab Monotherapy Is an Effective ..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S173 , 2022
Link: https://doi.org/10.1016/..
 
?
12

MDS-445 Magrolimab In Combination With Azacitidine for Pati..:

Sallman, David ; Malki, Monzr Al ; Asch, Adam...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S314-S315 , 2022
Link: https://doi.org/10.1016/..
 
?
13

Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Eff..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S117 , 2022
Link: https://doi.org/10.1016/..
 
?
14

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S387 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Oral Abstract: MDS-445 Magrolimab In Combination with Azaci..:

Sallman, David ; Malki, Monzr Al ; Asch, Adam...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S115 , 2022
Link: https://doi.org/10.1016/..
 
1-15